Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

5-azacytidine treatment reshapes clonal structure and alters mutation-dependent splicing in MDS patients

View Full Paper
Ask AI
Bookmark
Share

Authors

XZXuan ZhangDBDavid BernardiciusADAmy E. DeZern

Discussion

Loading...

Member takes

Overview

Multimodal analysis uncovers RUNX1's role in leukemic transformation and inflammatory pathway changes in MDS.

Key Points

  • Leukemic transformation implicated altered clonal dynamics and splicing profiles in MDS.
  • RUNX1 demonstrates key functions with distinct mutation-related therapeutic vulnerabilities.
  • Assessment using advanced multimodal single-cell profiling reveals critical insights into transcriptome profiles.
  • Highlights mutation-specific reprogramming and treatment response, indicating potential targets for MDS management.

Cite This Study

Zhang et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d798https://doi.org/10.1182/blood-2025-2054
View Full Paper
Ask AI
Bookmark
Share